Test Your ASN Knowledge!
The ASN 2022 PhysQuiz was created by the editorial staff at Physician’s Weekly.
Read MoreDec 16, 2022
The ASN 2022 PhysQuiz was created by the editorial staff at Physician’s Weekly.
Read MoreDec 16, 2022
Metabolic tumor volume (MTV) was reported at the 2022 annual meeting of the American Society of Hematology to be a predictive biomarker for patients with relapsed or refractory diffuse large B-cell lymphoma (rel/ref DLBCL) who...
Read MoreDec 15, 2022
measurable residual disease (MRD)-negative showed an overall survival (OS) benefit if they were...
Read MoreDec 15, 2022
Post-transplant cyclophosphamide/tacrolimus/mycophenolate mofetil outperformed...
Read MoreDec 15, 2022
Odronextamab, an investigational bi-specific antibody targeting CD20 and CD3, showed promising...
Read MoreDec 15, 2022
Consolidation high-dose chemotherapy followed by autologous stem cell transplantation (HCT/ASCT)...
Read MoreDec 15, 2022
Intensive chemotherapy, in advance of allogeneic hematopoietic cell transplantation (allo-HCT),...
Read MoreDec 15, 2022
The 5-year follow-up data of the CAPTIVATE study demonstrated that first-line ibrutinib plus...
Read MoreDec 15, 2022
In patients with previously untreated mantle cell lymphoma (MCL), autologous stem cell...
Read MoreDec 14, 2022
High-dose methotrexate was not associated with a reduction in the risk for CNS relapse compared...
Read MoreDec 14, 2022
Triplet therapy of azacitidine, venetoclax, and magrolimab was safe as first-line therapy in...
Read MoreDec 14, 2022
A curated ebook of recent studies, findings, and thought leader perspectives from AHA 2022.
Read MoreDec 14, 2022
A quiz based on the latest NMOSD news and research from ECTRIMS.
Read MoreDec 9, 2022
Almost one-third of residents with gout living in aged care facilities did not receive...
Read More